Equity Prepayment Facility drawdown
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your GDR notes
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces a further scheduled £600,000 draw down under the terms of the £5m Equity Prepayment Facility, which was previously announced by the Company on 31 March 2023. Investors have been granted 3,093,915 warrants equal to 40% of this drawdown divided by the Reference Price of 7.7572 pence. The exercise price of the warrants payable to the Company will be 140% of the Reference Price equating to 10.86 pence.
Capitalised terms in this announcement shall, unless the context demands otherwise, bear the meanings given to such terms in the announcement of the Facility made via RNS on 31 March 2023.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.